Published in PLoS One on June 09, 2010
Differentiation stage determines pathologic and protective allergen-specific CD4+ T-cell outcomes during specific immunotherapy. J Allergy Clin Immunol (2011) 2.04
Therapies for allergic inflammation: refining strategies to induce tolerance. Nat Med (2012) 1.75
Bee venom processes human skin lipids for presentation by CD1a. J Exp Med (2015) 1.62
Changes in antigen-specific T-cell number and function during oral desensitization in cow's milk allergy enabled with omalizumab. Mucosal Immunol (2012) 1.18
Mechanisms of allergen-specific immunotherapy and immune tolerance to allergens. World Allergy Organ J (2015) 1.03
Molecular and cellular mechanisms of food allergy and food tolerance. J Allergy Clin Immunol (2016) 0.90
Immunological mechanisms for desensitization and tolerance in food allergy. Semin Immunopathol (2012) 0.83
Elevated and cross-responsive CD1a-reactive T cells in bee and wasp venom allergic individuals. Eur J Immunol (2015) 0.82
Successful immunotherapy induces previously unidentified allergen-specific CD4+ T-cell subsets. Proc Natl Acad Sci U S A (2016) 0.82
Lack of allergy to timothy grass pollen is not a passive phenomenon but associated with the allergen-specific modulation of immune reactivity. Clin Exp Allergy (2016) 0.79
Mechanisms of immune tolerance to allergens in children. Korean J Pediatr (2013) 0.77
Direct ex-vivo evaluation of pneumococcal specific T-cells in healthy adults. PLoS One (2011) 0.77
Immunoregulatory T cell epitope peptides: the new frontier in allergy therapy. Clin Exp Allergy (2015) 0.77
Novel developments in the mechanisms of immune tolerance to allergens. Hum Vaccin Immunother (2012) 0.76
Deciphering the black box of food allergy mechanisms. Ann Allergy Asthma Immunol (2017) 0.76
T Cell Epitope Peptide Therapy for Allergic Diseases. Curr Allergy Asthma Rep (2016) 0.75
Pathogenesis of cerebral palsy through the prism of immune regulation of nervous tissue homeostasis: literature review. Childs Nerv Syst (2016) 0.75
Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol (2004) 17.40
Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur J Immunol (2007) 6.92
Induction of FoxP3 and acquisition of T regulatory activity by stimulated human CD4+CD25- T cells. J Clin Invest (2003) 6.42
Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med (1999) 5.46
A panel of MHC class I restricted viral peptides for use as a quality control for vaccine trial ELISPOT assays. J Immunol Methods (2002) 4.48
Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med (2000) 3.98
Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med (2004) 3.83
Regulatory T cells and intestinal homeostasis. Immunol Rev (2005) 3.82
Clinical and molecular features of the immunodysregulation, polyendocrinopathy, enteropathy, X linked (IPEX) syndrome. J Med Genet (2002) 3.61
IMGT, the international ImMunoGeneTics information system. Nucleic Acids Res (2005) 3.46
IMGT/V-QUEST, an integrated software program for immunoglobulin and T cell receptor V-J and V-D-J rearrangement analysis. Nucleic Acids Res (2004) 3.14
Sensitisation, asthma, and a modified Th2 response in children exposed to cat allergen: a population-based cross-sectional study. Lancet (2001) 3.06
IL-10 and TGF-beta cooperate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol (2003) 2.62
Role of interleukin 10 in specific immunotherapy. J Clin Invest (1998) 2.57
Suppression of airway eosinophilia by killed Mycobacterium vaccae-induced allergen-specific regulatory T-cells. Nat Med (2002) 2.51
Late asthmatic reactions induced by inhalation of allergen-derived T cell peptides. Am J Respir Crit Care Med (2003) 2.46
Clinical features and severity grading of anaphylaxis. J Allergy Clin Immunol (2004) 2.45
Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol (2004) 2.40
Effect of T-cell peptides derived from Fel d 1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet (2002) 2.38
Induction of IL-10+CD4+CD25+ T cells by grass pollen immunotherapy. J Allergy Clin Immunol (2003) 1.94
In vivo switch to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med (2008) 1.91
Immunological changes during specific immunotherapy of grass pollen allergy: reduced lymphoproliferative responses to allergen and shift from TH2 to TH1 in T-cell clones specific for Phl p 1, a major grass pollen allergen. Clin Exp Allergy (1997) 1.80
Influence of grass pollen immunotherapy on cellular infiltration and cytokine mRNA expression during allergen-induced late-phase cutaneous responses. J Clin Invest (1993) 1.66
Sublingual immunotherapy induces IL-10-producing T regulatory cells, allergen-specific T-cell tolerance, and immune deviation. J Allergy Clin Immunol (2007) 1.64
Modified Th2 responses at high-dose exposures to allergen: using an occupational model. Am J Respir Crit Care Med (2006) 1.52
Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol (1998) 1.52
Allergen immunotherapy decreases interleukin 4 production in CD4+ T cells from allergic individuals. J Exp Med (1993) 1.51
Bee venom immunotherapy results in decrease of IL-4 and IL-5 and increase of IFN-gamma secretion in specific allergen-stimulated T cell cultures. J Immunol (1995) 1.47
Grass pollen immunotherapy induces Foxp3-expressing CD4+ CD25+ cells in the nasal mucosa. J Allergy Clin Immunol (2008) 1.43
Generation of antigen-specific suppressor cells during allergy desensitization. N Engl J Med (1980) 1.40
Epitope-specific T cell tolerance to phospholipase A2 in bee venom immunotherapy and recovery by IL-2 and IL-15 in vitro. J Clin Invest (1996) 1.29
Mechanisms of immunotherapy: IgG revisited. Curr Opin Allergy Clin Immunol (2004) 1.26
T cell epitope immunotherapy induces a CD4+ T cell population with regulatory activity. PLoS Med (2005) 1.24
Insect venom immunotherapy induces interleukin-10 production and a Th2-to-Th1 shift, and changes surface marker expression in venom-allergic subjects. Eur J Immunol (1997) 1.22
Induction of interleukin-10 and suppressor of cytokine signalling-3 gene expression following peptide immunotherapy. Clin Exp Allergy (2006) 1.19
Varicella zoster virus glycoprotein E-specific CD4+ T cells show evidence of recent activation and effector differentiation, consistent with frequent exposure to replicative cycle antigens in healthy immune donors. Clin Exp Immunol (2008) 1.19
Glucocorticoids drive human CD8(+) T cell differentiation towards a phenotype with high IL-10 and reduced IL-4, IL-5 and IL-13 production. Eur J Immunol (2000) 1.18
Inhibition of IgE production and normalization of airways responsiveness by sensitized CD8 T cells in a mouse model of allergen-induced sensitization. J Immunol (1994) 1.18
Grass pollen immunotherapy inhibits allergen-induced infiltration of CD4+ T lymphocytes and eosinophils in the nasal mucosa and increases the number of cells expressing messenger RNA for interferon-gamma. J Allergy Clin Immunol (1996) 1.16
Allergen-specific production of interferon-gamma by peripheral blood mononuclear cells and CD8 T cells in allergic disease and following immunotherapy. Clin Exp Allergy (2000) 1.13
IL-10-induced anergy in peripheral T cell and reactivation by microenvironmental cytokines: two key steps in specific immunotherapy. FASEB J (1999) 1.13
Fel d 1-derived T cell peptide therapy induces recruitment of CD4+ CD25+; CD4+ interferon-gamma+ T helper type 1 cells to sites of allergen-induced late-phase skin reactions in cat-allergic subjects. Clin Exp Allergy (2005) 1.12
Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol (2001) 1.09
T-cell cytokine pattern at three time points during specific immunotherapy for mite-sensitive asthma. Clin Exp Allergy (2000) 1.08
Persistent central memory phenotype of circulating Fel d 1 peptide/DRB1*0101 tetramer-binding CD4+ T cells. J Allergy Clin Immunol (2006) 1.08
Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol (2007) 1.05
Application of heat killed Mycobacterium bovis-BCG into the lung inhibits the development of allergen-induced Th2 responses. Vaccine (2002) 1.01
The effect of Fel d 1-derived T-cell peptides on upper and lower airway outcome measurements in cat-allergic subjects. Allergy (2005) 1.01
Expansion of circulating Foxp3+)D25bright CD4+ T cells during specific venom immunotherapy. Clin Exp Allergy (2007) 1.01
Update on the current status of peptide immunotherapy. J Allergy Clin Immunol (2007) 1.01
Grass pollen immunotherapy for hayfever is associated with increases in local nasal but not peripheral Th1:Th2 cytokine ratios. Immunology (2002) 1.00
Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci U S A (2007) 1.00
Allergen-specific MHC class II tetramer+ cells are detectable in allergic, but not in nonallergic, individuals. J Immunol (2006) 0.97
Induction and differential regulation of bee venom phospholipase A2-specific human IgE and IgG4 antibodies in vitro requires allergen-specific and nonspecific activation of T and B cells. J Allergy Clin Immunol (1997) 0.95
A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J Allergy Clin Immunol (2003) 0.93
Proliferation and release of IL-5 and IFN-gamma by peripheral blood mononuclear cells from cat-allergic asthmatics and rhinitics, non-cat-allergic asthmatics, and normal controls to peptides derived from Fel d 1 chain 1. J Allergy Clin Immunol (2001) 0.92
Immunotherapy with Hymenoptera venoms. Position paper of the Working Group on Immunotherapy of the European Academy of Allergy and Clinical Immunology. Allergy (1987) 0.91
Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Int Arch Allergy Immunol (2005) 0.91
Effects of peptide therapy on ex vivo T-cell responses. J Allergy Clin Immunol (1998) 0.91
Suppression of allergen reactive Th2 mediated responses and pulmonary eosinophilia by intranasal administration of an immunodominant peptide is linked to IL-10 production. Vaccine (2003) 0.90
Combination of passive and active immunization in honeybee venom immunotherapy. J Allergy Clin Immunol (1987) 0.90
Bee venom immunotherapy induces a shift in cytokine responses from a TH-2 to a TH-1 dominant pattern: comparison of rush and conventional immunotherapy. Clin Exp Allergy (1995) 0.88
Generation of suppressor cells in atopic patients during immunotherapy that modulate IgE synthesis. J Allergy Clin Immunol (1987) 0.87
Immunotherapy in bee sting hypersensitivity. Bee venom versus wholebody extract. Allergy (1979) 0.87
Venom immunotherapy: comparison of "rush" vs "conventional" schedules. Ann Allergy (1980) 0.83
Induction of T 'regulatory' cells by standardized house dust mite immunotherapy: an increase in CD4+ CD25+ interleukin-10+ T cells expressing peripheral tissue trafficking markers. Clin Exp Allergy (2004) 0.83
Characterization of the human T cell response to antigen 5 from Vespula vulgaris (Ves v 5). Clin Exp Allergy (2005) 0.81
The effect of specific immunotherapy on T-cell receptor repertoire in patients with allergy to house-dust mite. Allergy (2003) 0.81
Oligoclonal analysis of the atopic T cell response to the group 1 allergen of Cynodon dactylon (bermuda grass) pollen: pre- and post-allergen-specific immunotherapy. Int Arch Allergy Immunol (2002) 0.81
Specific immunotherapy prevents increased levels of allergen-specific IL-4- and IL-13-producing cells during pollen season. Allergy (2001) 0.80
Defining the T cell antigen proteome of wasp venom. Clin Exp Allergy (2006) 0.79
Wasp venom immunotherapy induces a shift from IL-4-producing towards interferon-gamma-producing CD4+ and CD8+ T lymphocytes. Clin Exp Allergy (2001) 0.78
Specific immunotherapy downregulates peripheral blood CD4 and CD8 T-lymphocyte activation in grass pollen-sensitive asthma. Eur Respir J (1998) 0.76
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med (2002) 10.03
Snakebite mortality in India: a nationally representative mortality survey. PLoS Negl Trop Dis (2011) 3.98
Infection outcomes in patients with common variable immunodeficiency disorders: relationship to immunoglobulin therapy over 22 years. J Allergy Clin Immunol (2010) 3.65
TLR2 is expressed on activated T cells as a costimulatory receptor. Proc Natl Acad Sci U S A (2004) 3.04
UK malaria treatment guidelines. J Infect (2007) 3.00
Confronting the neglected problem of snake bite envenoming: the need for a global partnership. PLoS Med (2006) 2.87
Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol (2004) 2.28
A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med (2013) 2.11
Multiple-dose activated charcoal in acute self-poisoning: a randomised controlled trial. Lancet (2008) 1.98
The Global Snake Bite Initiative: an antidote for snake bite. Lancet (2010) 1.98
Amyloid-beta: a chameleon walking in two worlds: a review of the trophic and toxic properties of amyloid-beta. Brain Res Brain Res Rev (2003) 1.97
Socioeconomic disadvantage and acute coronary events: a spatiotemporal analysis. Epidemiology (2008) 1.68
Escaping high viral load exhaustion: CD8 cells with altered tetramer binding in chronic hepatitis B virus infection. J Exp Med (2002) 1.66
Snakebite envenoming from a global perspective: Towards an integrated approach. Toxicon (2009) 1.62
Distinctive epidemiologic and clinical features of common krait (Bungarus caeruleus) bites in Sri Lanka. Am J Trop Med Hyg (2008) 1.51
Dynamics of T cell responses in HIV infection. J Immunol (2002) 1.44
Immunopolarization of CD4+ and CD8+ T cells to Type-1-like is associated with melanocyte loss in human vitiligo. Lab Invest (2003) 1.41
Ending the drought: new strategies for improving the flow of affordable, effective antivenoms in Asia and Africa. J Proteomics (2011) 1.36
The hazards of gastric lavage for intentional self-poisoning in a resource poor location. Clin Toxicol (Phila) (2007) 1.32
Venom ophthalmia caused by venoms of spitting elapid and other snakes: Report of ten cases with review of epidemiology, clinical features, pathophysiology and management. Toxicon (2010) 1.31
Evaluation of the WHO revised criteria for classification of clinical disease severity in acute adult dengue infection. BMC Res Notes (2012) 1.22
Deaths from symptomatically identifiable furious rabies in India: a nationally representative mortality survey. PLoS Negl Trop Dis (2012) 1.18
Syndromic approach to treatment of snake bite in Sri Lanka based on results of a prospective national hospital-based survey of patients envenomed by identified snakes. Am J Trop Med Hyg (2009) 1.14
The need for full integration of snakebite envenoming within a global strategy to combat the neglected tropical diseases: the way forward. PLoS Negl Trop Dis (2013) 1.11
A simplified 4-site economical intradermal post-exposure rabies vaccine regimen: a randomised controlled comparison with standard methods. PLoS Negl Trop Dis (2008) 1.08
Cellular and cytokine correlates of severe dengue infection. PLoS One (2012) 1.08
Bites of venomous snakes. N Engl J Med (2002) 1.07
Allergen-specific CD8(+) T cells and atopic disease. J Clin Invest (2002) 1.07
Randomised controlled double-blind non-inferiority trial of two antivenoms for saw-scaled or carpet viper (Echis ocellatus) envenoming in Nigeria. PLoS Negl Trop Dis (2010) 1.07
Phenotypic analysis of human CD4+ T cells specific for immediate-early 63 protein of varicella-zoster virus. Eur J Immunol (2007) 1.05
The epidermis as an adjuvant. J Invest Dermatol (2012) 1.02
Preclinical assessment of the efficacy of a new antivenom (EchiTAb-Plus-ICP) for the treatment of viper envenoming in sub-Saharan Africa. Toxicon (2009) 1.02
Viral load, clinical disease severity and cellular immune responses in primary varicella zoster virus infection in Sri Lanka. PLoS One (2008) 1.02
Persistent high frequencies of varicella-zoster virus ORF4 protein-specific CD4+ T cells after primary infection. J Virol (2006) 1.01
Serum IL-10 as a marker of severe dengue infection. BMC Infect Dis (2013) 1.00
Bacterial superantigen facilitates epithelial presentation of allergen to T helper 2 cells. Proc Natl Acad Sci U S A (2007) 1.00
Snake bite: a neglected problem in twenty-first century India. Natl Med J India (2012) 0.99
Clinical trial of two antivenoms for the treatment of Bothrops and Lachesis bites in the north eastern Amazon region of Brazil. Trans R Soc Trop Med Hyg (2004) 0.99
CD4(-)CD8alphaalpha subset of CD1d-restricted NKT cells controls T cell expansion. J Immunol (2004) 0.98
IL-17 downregulates filaggrin and affects keratinocyte expression of genes associated with cellular adhesion. Exp Dermatol (2012) 0.97
The greater black krait (Bungarus niger), a newly recognized cause of neuro-myotoxic snake bite envenoming in Bangladesh. Brain (2010) 0.96
T cell responses in dengue viral infections. J Clin Virol (2013) 0.96
Value of retinal vein pulsation characteristics in predicting increased optic disc excavation. Br J Ophthalmol (2006) 0.96
Snake venomics of African spitting cobras: toxin composition and assessment of congeneric cross-reactivity of the pan-African EchiTAb-Plus-ICP antivenom by antivenomics and neutralization approaches. J Proteome Res (2011) 0.96
Immunomodulatory therapy to achieve maximum efficacy: doses, monitoring, compliance, and self-infusion at home. J Clin Immunol (2010) 0.96
Hyponatraemia, rhabdomyolysis, alterations in blood pressure and persistent mydriasis in patients envenomed by Malayan kraits (Bungarus candidus) in southern Viet Nam. Toxicon (2010) 0.94
Fatal diffuse thrombotic microangiopathy after a bite by the "Fer-de-Lance" pit viper (Bothrops lanceolatus) of Martinique. Am J Trop Med Hyg (2008) 0.91
Antivenomic assessment of the immunological reactivity of EchiTAb-Plus-ICP, an antivenom for the treatment of snakebite envenoming in sub-Saharan Africa. Am J Trop Med Hyg (2010) 0.90
Snake venomics of the Lesser Antillean pit vipers Bothrops caribbaeus and Bothrops lanceolatus: correlation with toxicological activities and immunoreactivity of a heterologous antivenom. J Proteome Res (2008) 0.89
Snake bite in Chittagong Division, Bangladesh: a study of bitten patients who developed no signs of systemic envenoming. Trans R Soc Trop Med Hyg (2010) 0.89
Immunoglobulin maintenance therapy in long-standing complex regional pain syndrome, an open study. Rheumatology (Oxford) (2013) 0.88
Crotaline snake bite in the Ecuadorian Amazon: randomised double blind comparative trial of three South American polyspecific antivenoms. BMJ (2004) 0.88
Human keratinocyte induction of rapid effector function in antigen-specific memory CD4+ and CD8+ T cells. Eur J Immunol (2007) 0.88
Efficacy and safety of two whole IgG polyvalent antivenoms, refined by caprylic acid fractionation with or without beta-propiolactone, in the treatment of Bothrops asper bites in Colombia. Trans R Soc Trop Med Hyg (2006) 0.88
Physical vulnerability and fatal self-harm in the elderly. Br J Psychiatry (2006) 0.87
Antibody deficiency secondary to chronic lymphocytic leukemia: Should patients be treated with prophylactic replacement immunoglobulin? J Clin Immunol (2014) 0.86
Intravenous ibuprofen (IV-ibuprofen) controls fever effectively in adults with acute uncomplicated Plasmodium falciparum malaria but prolongs parasitemia. Am J Trop Med Hyg (2010) 0.83
Antivenom therapy of carpet viper (Echis ocellatus) envenoming: effectiveness and strategies for delivery in West Africa. Toxicon (2013) 0.83
Haematological evaluation of patients bitten by the jararaca, Bothrops jararaca, in Brazil. Toxicon (2008) 0.83
Clinical, molecular, and cellular immunologic findings in patients with SP110-associated veno-occlusive disease with immunodeficiency syndrome. J Allergy Clin Immunol (2012) 0.82
The African challenge. Lancet (2002) 0.82
Isolation and characterization of cotiaractivase, a novel low molecular weight prothrombin activator from the venom of Bothrops cotiara. Biochim Biophys Acta (2006) 0.82
Study protocol: a randomised controlled trial of multiple and single dose activated charcoal for acute self-poisoning. BMC Emerg Med (2007) 0.81
Oligomeric MHC molecules and their homologues: state of the art. J Immunol Methods (2002) 0.81
Neurotoxic envenoming by South American coral snake (Micrurus lemniscatus helleri): case report from eastern Ecuador and review. Trans R Soc Trop Med Hyg (2008) 0.80
Apparent marked reduction in early antivenom reactions compared to historical controls: was it prophylaxis or method of administration? Toxicon (2009) 0.79
Venom phospholipases of Russell's vipers from Myanmar and eastern India--cloning, characterization and phylogeographic analysis. Biochim Biophys Acta (2007) 0.79
Interleukin-4 promotes human CD8 T cell expression of CCR7. Immunology (2006) 0.78
Spider bites: addressing mythology and poor evidence. Am J Trop Med Hyg (2005) 0.78
Rapid effector function of circulating CD4+ T cells specific for immunodominant regions of the conserved serine/threonine kinase found in Streptococcus pneumoniae (StkP) in healthy adults. FEMS Immunol Med Microbiol (2010) 0.77
Management of venomous bites and stings in British Military Personnel deployed in Iraq, Afghanistan and Cyprus. J R Army Med Corps (2008) 0.77
Non-front-fanged colubroid snakes: a current evidence-based analysis of medical significance. Toxicon (2013) 0.76
Acute pituitary insufficiency and hypokalaemia following envenoming by Russell's viper (Daboia russelii) in Sri Lanka: Exploring the pathophysiological mechanisms. Toxicon (2012) 0.76
Systemic effects induced by the venom of the snake Bothrops caribbaeus in a murine model. Toxicon (2012) 0.76
Use of antivenom in Vipera berus Bites--a comment. Wilderness Environ Med (2009) 0.75
Natural killer cells during primary varicella zoster virus infection. J Infect (2010) 0.75
Treatment of adder bites in dogs. Vet Rec (2013) 0.75
Proatheris superciliaris: the deadly venom of a rare and elusive snake revealed. Toxicon (2008) 0.75
On the use of analgesia in experimental toxinology. Toxicon (2013) 0.75
A novel fluorescent sensitive assay for detection of differential T cell mediated lysis of multiple adherent target cells. J Immunol Methods (2006) 0.75
Snakebite envenoming. Nat Rev Dis Prim (2017) 0.75